Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 6/20 | 0.45 |
| ▸ | CTSK | P43235 | 6/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25407355 | 1.00 | MEN1 (0.60) | MEN1GAAKMT2ASYKCTSS | |
| SCHEMBL12901343 | 1.00 | MEN1 (0.60) | MEN1GAAKMT2ASYKCTSS | |
| SCHEMBL1274536 | 0.91 | MEN1 (0.66) | MEN1GAAKMT2ASYKCTSS | |
| SCHEMBL3396578 | 0.86 | MEN1 (0.61) | MEN1GAAKMT2ASYKCTSS | |
| SCHEMBL13109033 | 0.86 | MEN1 (0.61) | MEN1GAAKMT2ASYKCTSS | |
| SCHEMBL13109049 | 0.86 | MEN1 (0.61) | MEN1GAAKMT2ASYKCTSS | |
| SCHEMBL12901342 | 0.86 | MEN1 (0.47) | MEN1GAAKMT2ASYKCTSS | |
| SCHEMBL28560564 | 0.86 | MEN1 (0.60) | MEN1GAAKMT2ASYKCTSS | |
| SCHEMBL6200619 | 0.85 | MEN1 (0.64) | MEN1GAAKMT2ACTSSCTSK | |
| SCHEMBL6200616 | 0.85 | MEN1 (0.64) | MEN1GAAKMT2ACTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227437-A1 | IMMUNOMODULATOR | HITGEN INC (CN) | 2023-07-20 | — | — | US | disclosed |
| EP-4183783-A1 | IMMUNOMODULATOR | Hitgen Inc. (CN) | 2023-05-24 | — | — | EP | disclosed |
| WO-2008155141-A2 | NOVEL FACULTATIVE CATONIC STEROLS | NOVOSOM AG (DE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227437-A1 | IMMUNOMODULATOR | IL17A, IL2, IL2RA | MEN1 3795/4885GAA 2382/4885KMT2A 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.